RxDoctor Payments Data

Stephanie Kuitunen, PA

Physician Assistant · Holdrege, NENPI 1851786537

Payments from drug & device makers

$628in general payments, 2019–2025

Across 22 payments — averaging $28.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$297
  • AbbVie$72
  • Urovant Sciences Inc$46
  • Axonics, Inc.$34
  • Convatec Inc.$32
  • ABC Home Medical Supply, Inc.$31
  • plus $116 from 5 others

What the payments were for

  • Food & beverage$48677%
  • Education$14223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc8$297
AbbVie3$72
Urovant Sciences Inc3$46
Axonics, Inc.1$34
Convatec Inc.1$32
ABC Home Medical Supply, Inc.1$31
180 Medical, Inc.1$30
Coloplast1$27
Hologic Sales And Service, LLC1$24
Antares Pharma, Inc.1$18
Therapeuticsmd, Inc.1$17

How this compares

$628 in reported general payments places this provider in the 60th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$64,400
Medicare patients
249
Services billed
929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron163$168,795
MyrbetriqMirabegron126$131,598
EstringEstradiol32$17,119
Estradiol182$12,444
PremarinEstrogens, Conjugated17$7,575
Methenamine Hippurate47$2,544
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$765
Clobetasol Propionate30$564
Trimethoprim20$553
NitrofurantoinNitrofurantoin Macrocrystal13$350
Cephalexin52$336
Cefdinir11$186
Fluconazole15$92
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$297$131,598126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Holdrege

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →